ESR1 and breast carcinoma: Tamoxifen: Tamoxifen is a selective estrogen receptor (ER) modulator, which antagonizes the action of endogenous estrogens by competitively binding ER and by preventing E2-induced proliferation of breast cancer cells, thus inhibiting estrogen-dependent tumor growth [41].